User:JonSDSUGrad/Sandbox/TEST11 Interleukin-6

From Wikipedia, the free encyclopedia


Interleukin 6 (interferon, beta 2), also known as IL6, is a human gene.

Interleukin 6 (interferon, beta 2)
PDB rendering based on 1alu.
Available structures: 1alu, 1il6, 1p9m, 2il6
Identifiers
Symbol(s) IL6; HGF; BSF2; HSF; IFNB2; IL-6
External IDs OMIM: 147620 MGI: 96559 HomoloGene: 502
RNA expression pattern

More reference expression data
Orthologs
Human Mouse
Entrez 3569 16193
Ensembl ENSG00000136244 ENSMUSG00000025746
Uniprot P05231 Q0PMN1
Refseq NM_000600 (mRNA)
NP_000591 (protein)		 NM_031168 (mRNA)
NP_112445 (protein)
Location Chr 7: 22.73 - 22.74 Mb Chr 5: 30.34 - 30.35 Mb
Pubmed search [1] [2]


[edit] Further reading

  • De Kloet ER, Oitzl MS, Schöbitz B (1994). "Cytokines and the brain corticosteroid receptor balance: relevance to pathophysiology of neuroendocrine-immune communication.". Psychoneuroendocrinology 19 (2): 121-34. PMID 8190832. 
  • Morishita R, Aoki M, Yo Y, Ogihara T (2003). "Hepatocyte growth factor as cardiovascular hormone: role of HGF in the pathogenesis of cardiovascular disease.". Endocr. J. 49 (3): 273-84. PMID 12201209. 
  • Ishihara K, Hirano T (2003). "IL-6 in autoimmune disease and chronic inflammatory proliferative disease.". Cytokine Growth Factor Rev. 13 (4-5): 357-68. PMID 12220549. 
  • Culig Z, Bartsch G, Hobisch A (2003). "Interleukin-6 regulates androgen receptor activity and prostate cancer cell growth.". Mol. Cell. Endocrinol. 197 (1-2): 231-8. PMID 12431817. 
  • Rattazzi M, Puato M, Faggin E, et al. (2004). "C-reactive protein and interleukin-6 in vascular disease: culprits or passive bystanders?". J. Hypertens. 21 (10): 1787-803. doi:10.1097/01.hjh.0000084735.53355.44. PMID 14508181. 
  • Tackey E, Lipsky PE, Illei GG (2005). "Rationale for interleukin-6 blockade in systemic lupus erythematosus.". Lupus 13 (5): 339-43. PMID 15230289. 
  • Berger FG (2005). "The interleukin-6 gene: a susceptibility factor that may contribute to racial and ethnic disparities in breast cancer mortality.". Breast Cancer Res. Treat. 88 (3): 281-5. doi:10.1007/s10549-004-0726-0. PMID 15609131. 
  • Stenvinkel P, Ketteler M, Johnson RJ, et al. (2005). "IL-10, IL-6, and TNF-alpha: central factors in the altered cytokine network of uremia--the good, the bad, and the ugly.". Kidney Int. 67 (4): 1216-33. doi:10.1111/j.1523-1755.2005.00200.x. PMID 15780075. 
  • Vgontzas AN, Bixler EO, Lin HM, et al. (2005). "IL-6 and its circadian secretion in humans.". Neuroimmunomodulation 12 (3): 131-40. doi:10.1159/000084844. PMID 15905620. 
  • Jones SA (2005). "Directing transition from innate to acquired immunity: defining a role for IL-6.". J. Immunol. 175 (6): 3463-8. PMID 16148087. 
  • Kristiansen OP, Mandrup-Poulsen T (2006). "Interleukin-6 and diabetes: the good, the bad, or the indifferent?". Diabetes 54 Suppl 2: S114-24. PMID 16306329. 
  • Copeland KF (2006). "Modulation of HIV-1 transcription by cytokines and chemokines.". Mini reviews in medicinal chemistry 5 (12): 1093-101. PMID 16375755. 
  • Mastorakos G, Ilias I (2007). "Interleukin-6: a cytokine and/or a major modulator of the response to somatic stress.". Ann. N. Y. Acad. Sci. 1088: 373-81. doi:10.1196/annals.1366.021. PMID 17192581. 
  • DubiÅ„ski A, Zdrojewicz Z (2007). "[The role of interleukin-6 in development and progression of atherosclerosis]". Pol. Merkur. Lekarski 22 (130): 291-4. PMID 17684929.